ArticleNature communications2025

Targeting cancer glutamine dependency with a first-in-class inhibitor of the mitochondrial glutamine transporter SLC1A5_var.

Yulseung Sung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.